Open-Label Extension of EryDex Study IEDAT-04-2022

Key facts

Sponsor

Quince Therapeutics S.p.A.

Principal Investigator

Dirk Thye, MD

Quince Therapeutics S.p.A.

Intervention

Dexamethasone sodium phosphate(drug)

Enrollment

101 enrolled

Eligibility

6 years · All sexes

Timeline

2024 – 2026

Study locations (21)

• University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence, Los Angeles, California, United States
• The Johns Hopkins Hospital, Division of pediatric allergy and immunology, Baltimore, Maryland, United States
• Saint Peter's University Hospital, Inc., New Brunswick, New Jersey, United States
• Cincinnati Children's Hospital, Division of neurology, Cincinnati, Ohio, United States
• UT Health Houston, Department of pediatrics, division of child & adolescent neurology, Houston, Texas, United States
• Copenhagen University Hospital, Rigshospitalet, Department of Pediatric Neurology, Copenhagen, Denmark, Denmark
• University Hospital Frankfurt, Pediatric and Adolescent Clinic, Frankfurt, Germany, Germany
• IKF Pneumologie GmbH & Co. KG; Institut für klinische Forschung Pneumologie Clinical Research Center Respiratory Diseases, Frankfurt am Main, Hesse, Germany
• Spedali Civili di Brescia, Pediatric immunology department, Brescia, Italy, Italy
• Policlinico Umberto I, La sapienza University, Department of neurosciences and menthal health, Roma, Italy, Italy
• Oslo University Hospital, Rikshospitalet, Division of Pediatric and Adolescent Medicine, Norwegian National Unit for Newborn Screening, Oslo, Norway, Norway
• MedPolonia sp zoo, Poznan, Poland
• Instytut "Pomnik-Centrum Zdrowia Dziecka", Immunology clinic, Warsaw, Poland
• Hospital Universitari Vall d'Hebron, Department of pediatric neurology, Barcelona, Spain, Spain
• Hospital Universitario La Paz, Department of pediatric neurology, Madrid, Spain, Spain
• +6 more locations on ClinicalTrials.gov

Collaborators

Biotrial

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Ataxia-telangiectasia

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE3NCT06673056
  A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
  IntraBio Inc
• ACTIVE NOT RECRUITINGPHASE2NCT04870866
  NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia
  University Hospital, Akershus

See all trials for Ataxia-telangiectasia →